Premium
Inhibitory effects of Candida albicans extracellular polysaccharides on mouse sarcoma 180
Author(s) -
Saltarelli Cora G.,
Paveljack Coppola C.
Publication year - 1980
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930150115
Subject(s) - candida albicans , sarcoma , medicine , extracellular , toxicity , glycoprotein , polysaccharide , pharmacology , immunology , pathology , cancer research , microbiology and biotechnology , biology , biochemistry
Extracellular glycoprotein produced by Candida albicans in chemically defined medium was used to treat solid Sarcoma 180 tumor cells implanted subcutaneously in Swiss female mice. Neither toxicity nor skin ulcerations surrounding the tumors was observed. Significant tumor inhibition was obtained using different methods to evaluate treatment effectiveness. Comparison of tumor weights after a single treatment (400 mg/kg, ip) on various days after transplantation indicated significant inhibition with a 10–80% regression rate. Multiple doses (800–2,000 mg/kg, ip) regressed 60–90% of all tumors. Subsequent dosage experiments showed an increased percentage of survivors for all treated groups and a significant decrease in tumor size. Studies of the glycoprotein material indicated that it was immunologically active.